Using Parametric Response Mapping to Detect Chronic Lung Injury after Hematopoietic Cell Transplant in Patients with Chronic GVHD or Lung Disease

What this Trial Is About

Researchers are studying patients who have undergone hematopoietic cell transplantation to better understand chronic graft versus host disease GVHD and chronic lung disease CLD. The study includes two groups one with newly diagnosed chronic GVHD and another with newly diagnosed CLD. The goal is to use Parametric Response Mapping PRM on CT scans to identify patterns that predict lung disease progression and survival outcomes in these patients. All participants will receive a non-contrast, high resolution CT scan with both inspiratory and expiratory imaging, pulmonary function tests PFT, and blood biomarker studies upon joining the study. A total of 375 subjects will be enrolled, including adults and children. Those in the chronic GVHD group who develop lung disease within 12 months will move to the lung disease group. Pulmonary function tests are recommended every three months for one year, with plasma samples collected at entry and after 12 months. Participants will undergo regular lung function testing and imaging during the year-long observation. Researchers will track survival without lung disease in the GVHD group and lung function decline in the lung disease group. They will also analyze PRM profiles and biomarker data from blood samples. This observational study aims to improve understanding of lung injury in hematopoietic cell transplant recipients, with safety and health monitored throughout the study period.

Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients